Efficacy News and Research

RSS

Industry sponsored clinical trials present a more favourable picture of reported findings

Studies reporting the results of industry sponsored clinical trials present a more favourable picture of the effects of drugs and medical devices than those reporting on non-industry sponsored trials, according to a new Cochrane systematic review. The researchers call for a rethink of the way that industry bias is handled in medical guidelines and reviews.

12 Dec 2012

Depression treatment ‘should target emotional control’

Being able to regulate emotions is a key driver of patients’ improvement in symptoms when undergoing treatment for depression, German researchers have shown.

11 Dec 2012

Depression treatment ‘should target emotional control’

Being able to regulate emotions is a key driver of patients’ improvement in symptoms when undergoing treatment for depression, German researchers have shown.

11 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Studies examine current treatment standards for patients with clotting disorders

Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes.

11 Dec 2012

Pomalidomide safe and effective in treating multiple myeloma

A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.

11 Dec 2012

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.

11 Dec 2012

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

11 Dec 2012

Alpha arrestins may play a role in cell signaling that is crucial to new drug development

A newly found understanding of receptor signaling may have revealed a better way to design drugs. A study from Nationwide Children's Hospital suggests that a newly identified group of proteins, alpha arrestins, may play a role in cell signaling that is crucial to new drug development.

11 Dec 2012

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company's investigational haematology/oncology compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA.

10 Dec 2012

CareView Communications and IASIS Healthcare sign multi-hospital agreement

CareView Communications, Inc., an information technology provider to the healthcare industry, today announced the signing of a multi-hospital agreement with IASIS Healthcare, a leading owner and operator of acute care hospitals in urban and suburban markets ("IASIS").

10 Dec 2012

Commercial ultrasonic frequency devices are not effective in repelling insects

Alternative means of controlling urban insect pests by using ultrasonic frequencies are available and marketed to the public. However, few of these devices have been demonstrated as being effective in repelling insect pests such as mosquitoes, cockroaches, or ants. Despite the lack of evidence for the efficacy of such devices, they continue to be sold and new versions targeting bed bugs are readily available.

10 Dec 2012

Cervical disc replacement: an interview with Joe Ross, VP of U.S. Marketing at LDR

Cervical disc replacement is a surgical procedure that involves removing a damaged or degenerated cervical disc and replacing it with an artificial disc device.

10 Dec 2012

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Efficacy News and Research

Industry sponsored clinical trials present a more favourable picture of reported findings

Depression treatment ‘should target emotional control’

Depression treatment ‘should target emotional control’

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Studies examine current treatment standards for patients with clotting disorders

Pomalidomide safe and effective in treating multiple myeloma

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Janssen announces U.S. prescribing information update for EDURANT tablets

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Alpha arrestins may play a role in cell signaling that is crucial to new drug development

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

CareView Communications and IASIS Healthcare sign multi-hospital agreement

Commercial ultrasonic frequency devices are not effective in repelling insects

Cervical disc replacement: an interview with Joe Ross, VP of U.S. Marketing at LDR

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Ibrutinib may effectively combat chronic lymphocytic leukemia

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News